Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Express Scripts
Johnson and Johnson
Medtronic
Moodys

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Oxcarbazepine - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for oxcarbazepine and what is the scope of patent protection?

Oxcarbazepine is the generic ingredient in three branded drugs marketed by Amneal Pharms, Sun Pharm Inds Ltd, West-ward Pharms Int, Novartis, Supernus Pharms, Ani Pharms Inc, Apotex Inc, Breckenridge Pharm, Glenmark Pharms Ltd, Jubilant Cadista, Sun Pharm Inds, and Taro, and is included in fourteen NDAs. There are ten patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Oxcarbazepine has sixty patent family members in thirty-three countries.

There are twenty-one drug master file entries for oxcarbazepine. Twenty-one suppliers are listed for this compound.

Drug Prices for oxcarbazepine

See drug prices for oxcarbazepine

Drug Sales Revenue Trends for oxcarbazepine

See drug sales revenues for oxcarbazepine

Recent Clinical Trials for oxcarbazepine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eisai Inc.Phase 4
Weill Medical College of Cornell UniversityPhase 4
UCB Biopharma S.P.R.L.Phase 1

See all oxcarbazepine clinical trials

Recent Litigation for oxcarbazepine

Identify potential future generic entrants

District Court Litigation
Case NameDate
Supernus Pharmaceuticals, Inc v. Actavis Inc.2016-02-24
SUPERNUS PHARMACEUTICALS, INC. v. ACTAVIS INC.2015-04-07
SUPERNUS PHARMACEUTICALS, INC. v. TWI PHARMACEUTICALS, INC.2015-01-16

See all oxcarbazepine litigation

Pharmacology for oxcarbazepine
Synonyms for oxcarbazepine
10-oxo-10,11-dihydro-5H-dibenz(b,f)azepin-5-carboxamide
10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide
10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide #
10,11-Dihydro-10-oxo-5H-debenz(b,f)azepine-5-carboxamide
10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide
10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepin-5-carbonsaeureamid
10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide
10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide; Oxacarbazepine
10,11-Dihydro-10-oxo-5H-dibenzo(Z)[b,f]azepine-5-carboxamide
10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide
28721-07-5
5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine
5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide
5H-Dibenz(b,f)azepine-5-carboxamide, 10,11-dihydro-10-oxo-
5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo-
721O075
9-oxo-2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-2-carboxamide
9-oxo-2-azatricyclo[9.4.0.0;{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-2-carboxamide
AB0012847
AB00393017_15
AB00393017_16
AB00393017-12
AB00393017-14
AB1004555
AC-3483
AC1L1RCU
AC1Q6NA8
AKOS005516529
AM20040094
AN-6739
API0003702
BB_SC-01874
BBL010789
BC204104
BCP28260
BDBM34179
BG0593
BIDD:GT0078
BRD-K04196797-001-12-9
BSPBio_003457
C-15585
C07492
CAS-28721-07-5
CC-33410
CCG-39509
CHEBI:7824
CHEMBL1068
cid_34312
CPD000048684
CS-1869
CTRLABGOLIVAIY-UHFFFAOYSA-N
D00533
DB00776
DSSTox_CID_25703
DSSTox_GSID_45703
DSSTox_RID_81075
DTXSID0045703
EINECS 249-188-8
EN300-123538
Epilexter
Epliga
FT-0630543
GP 47680
GP-47680
GTPL7254
HMS1922H17
HMS2051O04
HMS2090F13
HMS2093E10
HMS2231B12
HMS3369J22
HMS3393O04
HMS3657O11
HMS3713I10
HSDB 7524
HY-B0114
I06-0072
J10384
KBio2_002155
KBio2_004723
KBio2_007291
KBio3_002677
KBioGR_001248
KBioSS_002155
KIN-493
KS-5197
LS-60365
MCULE-9100100302
MFCD00865307
MLS000084586
MLS000759520
MLS001201742
MLS001424025
MLS006011855
MolPort-001-685-316
NC00088
NCGC00065934-02
NCGC00065934-03
NCGC00065934-04
NCGC00065934-05
NCGC00065934-06
NSC-758693
NSC758693
O0363
OCBZ
Opera_ID_818
Oxacarbazepine
Oxcarbamazepine
Oxcarbazepime
Oxcarbazepin
Oxcarbazepina
Oxcarbazepina [INN-Spanish]
Oxcarbazepine (JAN/USAN/INN)
Oxcarbazepine [INN]
Oxcarbazepine [USAN:USP:INN:BAN]
Oxcarbazepine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material
Oxcarbazepine-13C6 solution, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material
Oxcarbazepine-d4
Oxcarbazepine, >=98% (HPLC), solid
Oxcarbazepine, analytical standard
Oxcarbazepine, European Pharmacopoeia (EP) Reference Standard
Oxcarbazepine, Pharmaceutical Secondary Standard; Certified Reference Material
Oxcarbazepine, United States Pharmacopeia (USP) Reference Standard
Oxcarbazepinum
Oxcarbazepinum [INN-Latin]
Oxtellar (TN)
Oxtellar XR
Pharmakon1600-01504243
regid866068
s1391
SAM001246754
SBI-0206772.P001
SC-16252
SCHEMBL35129
SMR000048684
SPBio_000345
Spectrum_001675
SPECTRUM1504243
Spectrum2_000483
Spectrum3_001669
Spectrum4_000634
Spectrum5_001869
SPN-804
SR-01000612612
SR-01000612612-4
SR-01000612612-6
STK594696
SW197468-3
Timox
Tox21_110983
Tox21_110983_1
Trileptal
Trileptal (TN)
UNII-VZI5B1W380
VZI5B1W380
W-107033
W-2542
ZB000586
ZINC4724

US Patents and Regulatory Information for oxcarbazepine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-002 Oct 19, 2012 RX Yes No   Start Trial   Start Trial   Start Trial
Taro OXCARBAZEPINE oxcarbazepine TABLET;ORAL 077801-001 Nov 15, 2007 AB RX No No   Start Trial   Start Trial   Start Trial
Breckenridge Pharm OXCARBAZEPINE oxcarbazepine TABLET;ORAL 078069-003 Jan 11, 2008 AB RX No No   Start Trial   Start Trial   Start Trial
West-ward Pharms Int OXCARBAZEPINE oxcarbazepine TABLET;ORAL 077795-003 Oct 9, 2007 AB RX No No   Start Trial   Start Trial   Start Trial
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No   Start Trial   Start Trial   Start Trial
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for oxcarbazepine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis TRILEPTAL oxcarbazepine SUSPENSION;ORAL 021285-001 May 25, 2001   Start Trial   Start Trial
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-002 Jan 14, 2000   Start Trial   Start Trial
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-003 Jan 14, 2000   Start Trial   Start Trial
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-001 Jan 14, 2000   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Moodys
Merck
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.